Relationship of serum vitamin D with hepatic fibrosis in patients with chronic hepatitis C
DOI:
https://doi.org/10.18203/2320-6012.ijrms20204239Keywords:
Vitamin D, Liver fibrosis, Chronic hepatitis CAbstract
Background: Serum vitamin D concentration is proposed to have an important role on outcome in patients with chronic hepatitis C virus (HCV) infection. A few studies have shown an inverse association of vitamin D level with stage of fibrosis. The aim of the present study was to verify whether serum vitamin D level is an independent predictor of significant hepatic fibrosis.
Methods: Seventy-two treatment naive chronic HCV subjects and 40 healthy age and sex matched controls were included in the study. A serum vitamin D level was assessed in both HCV subjects and controls, and liver biopsy was performed in all HCV subjects to assess for stage of fibrosis.
Results: Serum vitamin D levels were significantly lower HCV patients in comparison to age and sex matched controls (18.04±6.92 versus 21.53±8.2, p<0.01). Most common genotype in HCV patients was genotype 3 (62.5%) and blood transfusion was the most common mode of transmission (28%) followed by intravenous drug user (IVDU) (17%). The HCV patients with vitamin D level <20 ng/ml had higher metavir score as compared to vitamin D≥20 ng/ml (1.67±0.66 versus 2.5±0.67, p<0.001). Both univariate and multivariate analysis performed using logistic regression revealed that vitamin D<20 ng/dl is a significant negative predictor of liver fibrosis (p<0.05).
Conclusions: Chronic HCV patients had significantly lower vitamin D levels as compared to healthy controls. Serum vitamin D was a negative predictor of stage of fibrosis in patients with chronic hepatitis C.
References
Chung RT, Baumert TF. Curing chronic hepatitis C–the arc of a medical triumph. N Engl J Med. 2014;370:1576-8.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyanset V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-128.
Dhiman RK. Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability? J Clin Exp Hepatol. 2014;4:85-6.
Dixit VK, Ghosh JK, Lamtha SC, Kaushik P, Goyal SK, Behera MK, Singh N, Jain AK. Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C—A Reappraisal from a Tertiary Care Center in Northern India. J Clin Exp Hepatol. 2014;4:101-5.
Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011;17:5184-90.
Bitetto D, Fattovich G, Fabris C, Ceriani C, Falleti E, Fornasiere E. Complementary role of vitamin D deficiency and the IL-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatol. 2011;53:1118-26.
Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014;20:11033-53.
Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095-100.
Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59:881-6.
Gutierrez JA, Parikh N, Branch AD. Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis. 2011;31:387-98.
Cholongitas E, Theocharidou E, Goulis J, Tsochatzis E, Akriviadis E, Burroughs AK. Review article: the extra-skeletal effects of vitamin D in chronic hepatitis C infection. Aliment Pharmacol Ther. 2012;35:634-46.
Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol. 2012;57:897-909.
Massard, J, Ratziu, V, Thabut, D: Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:19-24.
Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
Rahman AH, Branch AD. Vitamin D for your patients with chronic hepatitis C? J Hepatol. 2013;58:184‐9.
Keane JT, Elangovan H, Stokes RA, Gunton JE. Vitamin D and the Liver-Correlation or Cause? Nutrients. 2018;10:496.
Villar LM, Del Campo JA, Ranchal I, Lampe E, Romero-Gomez M. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2013;19:5917-24.
Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatol. 2010;51:1158-67.
Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatol. 2012;56:49-56.
Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol. 2013;58:467-72.
Behera MK, Shukla SK, Dixit VK, Nath P, Abhilash VB, Asati PK, et al. Effect of vitamin D supplementation on sustained virological response in genotype 1/4 chronic hepatitis C treatment-naïve patients from India. Indian J Med Res. 2018;148:200-6.
Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut. 2011;60:1728-37.
Gupta V, Kumar A, Sharma P, Tyagi P, Bansal N, Singla V, Arora A. Sustained Virological Response Rates to Antiviral Therapy in Genotype 1 and 3 Chronic Hepatitis C Patients: A Study from North India. J Clin Exp Hepatol. 2014;4:73.
Hu KQ, Yang H, Lin YC, Lindsay KL, Redeker AG. Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States Int J Med Sci. 2004;1:92-100.
Abraham R, Ramakrishna B, Balekuduru A, Daniel HD, Abraham P, Eapen CE, et al. Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease. Indian J Gastroenterol. 2009;28:53-8.
Singh S, Gupta R, Malhotra V, Sarin SK Predictors of histological activity and fibrosis in chronic hepatitis C infection: A study from North India. Indian J Pathol Microbiol. 2010;53:238-43.
